Fort Washington Investment Advisors Inc. OH Sells 90,613 Shares of Amgen Inc. $AMGN

Fort Washington Investment Advisors Inc. OH lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 98.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 995 shares of the medical research company’s stock after selling 90,613 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Amgen were worth $419,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. raised its position in Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. State Street Corp lifted its stake in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Amgen by 12.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after buying an additional 605,928 shares during the period. Bank of America Corp DE purchased a new position in shares of Amgen during the second quarter worth $1,831,903,000. Finally, Invesco Ltd. boosted its position in shares of Amgen by 7.2% during the fourth quarter. Invesco Ltd. now owns 4,788,460 shares of the medical research company’s stock worth $1,567,311,000 after buying an additional 321,173 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 in the last ninety days. 0.85% of the stock is owned by corporate insiders.

Amgen Stock Down 0.4%

Amgen stock opened at $432.49 on Friday. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The stock’s fifty day simple moving average is $415.54 and its 200-day simple moving average is $374.76. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market capitalization of $233.82 billion, a P/E ratio of 26.88, a P/E/G ratio of 3.18 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. Amgen’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on AMGN shares. Canaccord Genuity Group lifted their price objective on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Weiss Ratings raised Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Sanford C. Bernstein raised their target price on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Royal Bank Of Canada raised their target price on Amgen from $400.00 to $430.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. Finally, BMO Capital Markets dropped their target price on Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $387.93.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.